Oxadiazolines as Photoreleasable Labels for Drug Target Identification
Journal of the American Chemical Society · 2024
DOI: 10.1021/jacs.4c06936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2024. Verfasst von Corentin Bon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland. Hauptthemen laut MEDLINE: Oxadiazoles, Photoaffinity Labels. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Novartis Institutes for BioMedical Research.
Abstract (Originalsprache)
Photoaffinity labeling is a widely used technique for studying ligand-protein and protein-protein interactions. Traditional photoaffinity labels utilize nonspecific C-H bond insertion reactions mediated by a highly reactive intermediate. Despite being the most widely used photoaffinity labels, diazirines exhibit limited compatibility with downstream organic reactions and suffer from storage stability concerns. This study introduces oxadiazolines as innovative and complementary photoactivatable labels for addition to the toolbox and demonstrates their application in vitro and through in cellulo labeling experiments. Oxadiazolines can be easily synthesized from ketone moieties and cleaved with 302-330 nm light to cleanly liberate a diazo reactive moiety that can covalently modify nucleophilic amino acid residues. Notably, oxadiazolines are compatible with various organic reaction conditions and functional groups, allowing for the exploration of a large chemical space. Several known inhibitors featuring the oxadiazoline functionality were prepared without affecting their binding affinity. Furthermore, we confirmed the ability of oxadiazolines to form covalent bonds with proteins upon UV-irradiation, both in vitro and in cellulo, yielding comparable results to those of the matched diazirine compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland.
- Discovery Sciences, Novartis Biomedical Research, Novartis Pharma AG, Basel 4056, Switzerland.
- Chemical and Analytical Development, Novartis Development, Novartis Pharma AG, Basel 4056, Switzerland.
- Discovery Sciences, Novartis Biomedical Research, Novartis Pharma AG, Cambridge, Massachusetts 02139, United States.
ORCID-Profile: Corentin Bon, Fabio Lima, Cara E Brocklehurst
Förderung
- Novartis Institutes for BioMedical Research
Zitieren
APA
Bon, C., Goretzki, B., Flamme, M., Shelton, C., Davis, H., Lima, F., Garcia, F., Brittain, S., & Brocklehurst, C. E. (2024). Oxadiazolines as Photoreleasable Labels for Drug Target Identification. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.4c06936
Vancouver
Bon C, Goretzki B, Flamme M, Shelton C, Davis H, Lima F, et al. Oxadiazolines as Photoreleasable Labels for Drug Target Identification. Journal of the American Chemical Society. 2024. doi:10.1021/jacs.4c06936
BibTeX
@article{Bon2024,
author = {Bon, Corentin and Goretzki, Benedikt and Flamme, Marie and Shelton, Claude and Davis, Holly and Lima, Fabio and Garcia, Francisco and Brittain, Scott and Brocklehurst, Cara E},
title = {Oxadiazolines as Photoreleasable Labels for Drug Target Identification},
journal = {Journal of the American Chemical Society},
year = {2024},
doi = {10.1021/jacs.4c06936}
}
EUVIMED